Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Exkivity is approved for adults with advanced non-small-cell lung cancer with specific EGFR mutations.
Many older people have biomarkers indicative of a strong response to checkpoint inhibitors.
When cancer treatments zap your desire for food, certain meals and methods can help restore it.
Fall care, comfort and the healing power of hope
Nearly one in three of the articles you’ll find contain misinformation that’s often harmful.
COVID-19 vaccines are safe for people with cancer.
Here are some questions to ask your care team about how best to manage small-cell lung cancer.
The IDH1 inhibitor is the third medication approved this year for hard-to-treat bile duct cancer.
Researchers provide updates on the clinical trial of a new drug to improve the long-term survival of patients facing advanced melanoma
In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.
The booster is recommended for organ transplant recipients, people receiving cancer treatment and people with advanced or untreated HIV.
Targeted therapy and immunotherapy combination doubles response rate for people with advanced renal cell carcinoma.
This is the first immunotherapy approved for previously untreated triple-negative breast cancer that is likely to relapse.
A cancer therapy that delivers radiation directly to cancer cells may represent the newest advance in the treatment of prostate cancer.
Some people with blood cancers, however, may not be as well protected.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.